A carregar...
CCN5 activation by free or encapsulated EGCG is required to render triple‐negative breast cancer cell viability and tumor progression
Epigallocatechin‐3‐gallate (EGCG) has been considered an anticancer agent despite conflicting and discrepant bioavailability views. EGCG impairs the viability and self‐renewal capacity of triple‐negative breast cancer (TNBC) cells and makes them sensitive to estrogen via activating ER‐α. Surprisingl...
Na minha lista:
| Publicado no: | Pharmacol Res Perspect |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7981588/ https://ncbi.nlm.nih.gov/pubmed/33745223 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.753 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|